AGENUS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.69 USD | +3.84% |
|
+15.20% | -5.24% |
Financials (USD)
| Sales 2024 * | 206M | Sales 2025 * | 183M | Capitalization | 329M |
|---|---|---|---|---|---|
| Net income 2024 * | -175M | Net income 2025 * | -223M | EV / Sales 2024 * | 1.6 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.8 x |
| P/E ratio 2024 * |
-1.76
x | P/E ratio 2025 * |
-1.81
x | Employees | 389 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.78% |
More Fundamentals
* Assessed data
More news
Latest transcript on Agenus Inc.
More recommendations
More press releases
| 1 day | +3.84% | ||
| 1 week | +15.20% | ||
| 1 month | +29.46% | ||
| 3 months | +17.09% | ||
| 6 months | +0.95% | ||
| Current year | -5.24% |
1 week
13.85
16.34
1 month
10.0516.34
Current year
4.7818.98
1 year
4.7842.60
3 years
4.78135.80
5 years
4.78135.80
10 years
4.78203.20
| Managers | Title | Age | Since |
|---|---|---|---|
Garo Armen
CEO | Chief Executive Officer | 71 | 94-03-30 |
| Director of Finance/CFO | 58 | 95-12-31 | |
Craig Winter
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Garo Armen
CEO | Chief Executive Officer | 71 | 94-03-30 |
| Director/Board Member | 66 | 16-05-16 | |
Susan Hirsch
BRD | Director/Board Member | 71 | 20-10-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.15% | 25 M€ | -2.35% | - | |
| 0.03% | 1,487 M€ | +7.77% | - | |
| 0.01% | 746 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 15.69 | +3.84% | 585,522 |
| 24-05-30 | 15.11 | +0.53% | 409,566 |
| 24-05-29 | 15.03 | -1.44% | 851,565 |
| 24-05-28 | 15.25 | +11.97% | 1,071,757 |
| 24-05-24 | 13.62 | +10.28% | 695,430 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15.69
USD
Average target price
44.25
USD
Spread / Average Target
+182.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.24% | 329M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +0.04% | 12.16B | |
| +25.12% | 12.21B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- AGEN Stock
